Carasent AB (publ) (STO:CARA)
23.70
-0.20 (-0.84%)
Feb 10, 2026, 5:29 PM CET
Carasent AB Revenue
Carasent AB had revenue of 82.20M SEK in the quarter ending September 30, 2025, with 27.36% growth. This brings the company's revenue in the last twelve months to 328.99M, up 22.03% year-over-year. In the year 2024, Carasent AB had annual revenue of 275.26M with 12.27% growth.
Revenue (ttm)
328.99M
Revenue Growth
+22.03%
P/S Ratio
5.08
Revenue / Employee
1.68M
Employees
196
Market Cap
1.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275.26M | 30.08M | 12.27% |
| Dec 31, 2023 | 245.18M | 38.59M | 18.68% |
| Dec 31, 2022 | 206.60M | 65.86M | 46.79% |
| Dec 31, 2021 | 140.74M | 73.11M | 108.12% |
| Dec 31, 2020 | 67.62M | 16.69M | 32.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 34.97B |
| Swedish Orphan Biovitrum AB | 28.24B |
| Humana AB | 10.08B |
| Sectra AB | 3.47B |
| Camurus AB | 2.35B |
| Stille AB | 553.99M |
| EQL Pharma AB | 425.75M |
| BioInvent International AB | 244.85M |